4D Molecular Therapeutics Ownership | Who Owns 4D Molecular Therapeutics?
4D Molecular Therapeutics Ownership Summary
4D Molecular Therapeutics is owned by 85.49% institutional investors, 3.55% insiders, and 10.96% retail investors. Blackrock is the largest institutional shareholder, holding 9.94% of FDMT shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 3.32% of its assets in 4D Molecular Therapeutics shares.
FDMT Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | 4D Molecular Therapeutics | 85.49% | 3.55% | 10.96% |
| Sector | Healthcare Stocks | 35.75% | 11.89% | 52.37% |
| Industry | Biotech Stocks | 36.05% | 11.82% | 52.13% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Blackrock | 4.90M | 9.94% | $102.79M |
| Janus henderson group | 5.25M | 9.06% | $48.87M |
| Ra capital management | 5.05M | 8.72% | $47.01M |
| Goldman sachs group | 4.21M | 7.26% | $39.15M |
| Blackrock funding, inc. /de | 4.15M | 7.16% | $38.59M |
| Novo | 3.65M | 6.30% | $33.99M |
| Vanguard group | 3.09M | 5.51% | $23.20M |
| Bvf inc/il | 2.88M | 4.97% | $26.81M |
| State street | 2.71M | 4.67% | $25.21M |
| Armistice capital | 2.00M | 3.45% | $18.62M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Novo | 3.65M | 2.75% | $33.99M |
| Propel bio management | 380.42K | 2.26% | $3.58M |
| Peapod lane capital | 241.48K | 1.81% | $2.21M |
| Bvf inc/il | 2.88M | 0.85% | $26.81M |
| Exome asset management | 130.56K | 0.63% | $1.22M |
| Parkman healthcare partners | 522.58K | 0.50% | $4.87M |
| Ra capital management | 5.05M | 0.50% | $47.01M |
| Armistice capital | 2.00M | 0.33% | $18.62M |
| Privium fund management b.v. | 170.26K | 0.33% | $1.59M |
| Rangeley capital | 31.46K | 0.28% | $292.94K |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Blackrock | 4.90M | 0.00% | 612.35K |
| Janus henderson group | 5.25M | 0.02% | 611.28K |
| Vanguard group | 3.09M | 0.00% | 518.40K |
| Norges bank | 500.82K | 0.00% | 500.82K |
| Nuveen | 561.80K | 0.00% | 403.04K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Viking global investors lp | - | - | -2.93M |
| Bvf inc/il | 2.88M | 0.85% | -1.75M |
| Point72 asset management | - | - | -1.54M |
| Braidwell lp | - | - | -1.23M |
| Casdin capital | - | - | -1.15M |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Norges bank | 500.82K | 0.00% | 500.82K | $2.79M |
| Propel bio management | 380.42K | 2.26% | 380.42K | $3.58M |
| Vanguard fiduciary trust | 269.30K | 0.00% | 269.30K | $2.51M |
| Exome asset management | 130.56K | 0.63% | 130.56K | $1.22M |
| Hudson bay capital management lp | 113.30K | 0.01% | 113.30K | $2.38M |
Sold Out
| Holder | Change |
|---|---|
| Innealta capital | -4.00 |
| Nelson, van denburg & campbell wealth management group | -8.00 |
| Allspring global investments | -27.00 |
| Ronald blue trust | -36.00 |
| Ikarian capital | -40.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | 151 | -2.58% | 49,527,045 | -7.29% | 85 | 0.94% | 68 | -21.84% | 46 | 24.32% |
| Dec 31, 2025 | 40 | -70.59% | 5,592,450 | -85.86% | 9 | 0.20% | 21 | -69.12% | 10 | -77.78% |
| Sep 30, 2025 | 39 | -65.49% | 6,758,953 | -80.69% | 12 | 0.31% | 21 | -62.50% | 11 | -69.44% |
| Jun 30, 2025 | 120 | -4.00% | 40,390,122 | -6.26% | 72 | 1.21% | 58 | 23.40% | 39 | -35.00% |
| Mar 31, 2025 | 125 | -14.38% | 43,088,441 | -8.05% | 77 | 1.09% | 47 | -43.37% | 60 | 36.36% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Vanguard US Total Market Shares ETF | 1.54M | 3.32% | - |
| Vanguard Total Stock Mkt Idx Inv | 1.71M | 3.26% | - |
| State Street® SPDR® S&P® Biotech ETF | 1.47M | 2.81% | -9.13K |
| SPDR® S&P Biotech ETF | 986.40K | 2.13% | 14.03K |
| iShares Russell 2000 ETF | 1.07M | 2.04% | 9.83K |
| Janus Henderson Gbl Life Sciences Divers | 851.19K | 1.67% | 851.19K |
| Janus Henderson Global Life Sciences | 843.75K | 1.61% | 1.23K |
| Janus Henderson Global Life Sciences D | 843.75K | 1.61% | 3.59K |
| Polar Capital Healthcare Opports Inc | 790.16K | 1.52% | - |
| Janus Global Life Science AUSD | 782.98K | 1.50% | 38.58K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Jun 30, 2026 | Bizily Scott | Chief Legal Officer | Sell | $91.92K |
| Jun 23, 2026 | Bizily Scott | Chief Legal Officer | Sell | $117.72K |
| Jun 22, 2026 | Kirn David | See Remarks | Sell | $1.20M |
| Jun 01, 2026 | Kirn David | See Remarks | Sell | $19.26K |
| Mar 20, 2026 | Gupta Ashoo | VP, Finance and Controller | Sell | $2.67K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q2 | - | 4 |
| 2026 Q1 | - | 2 |
| 2025 Q4 | - | 7 |
| 2025 Q3 | - | 1 |
| 2025 Q2 | - | - |
FDMT Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools